Rockefeller Capital Management L.P. Sells 7,037 Shares of Sanofi (NASDAQ:SNY)

Rockefeller Capital Management L.P. trimmed its position in Sanofi (NASDAQ:SNY) by 2.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 353,245 shares of the company’s stock after selling 7,037 shares during the period. Rockefeller Capital Management L.P.’s holdings in Sanofi were worth $17,037,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in Sanofi by 26.3% during the fourth quarter. Sterling Capital Management LLC now owns 16,004 shares of the company’s stock worth $772,000 after acquiring an additional 3,329 shares during the period. Argent Trust Co raised its stake in shares of Sanofi by 4.0% during the 4th quarter. Argent Trust Co now owns 25,696 shares of the company’s stock worth $1,239,000 after purchasing an additional 996 shares during the period. Neuberger Berman Group LLC boosted its holdings in shares of Sanofi by 13.7% in the 4th quarter. Neuberger Berman Group LLC now owns 20,041 shares of the company’s stock worth $967,000 after buying an additional 2,411 shares during the last quarter. Scotia Capital Inc. grew its position in Sanofi by 7.1% during the fourth quarter. Scotia Capital Inc. now owns 8,677 shares of the company’s stock valued at $419,000 after buying an additional 572 shares during the period. Finally, Bessemer Group Inc. increased its holdings in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Up 0.7 %

SNY opened at $51.84 on Tuesday. The company has a 50 day moving average of $54.94 and a 200 day moving average of $52.31. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12. The company has a market cap of $130.96 billion, a PE ratio of 20.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.